Market Overview

UPDATE: Jefferies Upgrades Pfizer from Hold to Buy, Boosts Target to $38

Share:
Related PFE
S&P 500 Index Futures Trading Lower In Choppy, Volatile Session
Alliance Foundation Trials and Austrian Breast & Colorectal Cancer Study Group Open Largest Global Phase 3 Trial of Targeted Therapy, IBRANCE, for Patients with Hormone Receptor–Positive Early Breast Cancer
4 IBD 50 Drugmakers Getting Lift From New Treatments (Investor's Business Daily)

Pfizer (NYSE: PFE) has received an upgraded rating from Hold to Buy and a raised price target from $33 to $38 at Jefferies Tuesday morning.

Pfizer's upgrades follows acknowledgments that Oncology and restructuring are key themes for the Pharma sector and Pfizer has both of those covered with palbociclib looking like it could launch before year end, according to the firm's Jeffery Holland.

The Jefferies analyst expects the market to soon be reflecting incremental value in the shares based on the drivers above, adding significant upside to the companies shares.

Shares of Pfizer are up 2.7 percent to $31.42 at last check following the upgrade.

Latest Ratings for PFE

DateFirmActionFromTo
Aug 2015JefferiesMaintainsBuy
Jun 2015JefferiesInitiates Coverage onOverweight
Jun 2015Piper JaffrayInitiates Coverage onOverweight

View More Analyst Ratings for PFE
View the Latest Analyst Ratings

Posted-In: Analyst Color News Upgrades Price Target Analyst Ratings

 

Related Articles (PFE)

View Comments and Join the Discussion!

Get Benzinga's Newsletters